Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Cancer Vaccines Market Size And Revenue Outlook Through 2030
The cancer vaccines market has seen rapid expansion in its size over recent years. It is projected to grow from $9.36 billion in 2025 to $10.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.9%. This historical growth can be attributed to factors such as the increasing global prevalence of cancer, the limited effectiveness of conventional cancer treatments, rising awareness of cancer immunotherapy, growing investment in oncology research, and early regulatory approvals of cancer vaccines.
The cancer vaccines market is projected for significant expansion over the coming years. This market is anticipated to reach $18.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.3%. This projected expansion during the forecast period stems from progress in vaccine platforms and delivery mechanisms, a greater uptake of individualized cancer vaccines, an increase in clinical pipelines for therapeutic vaccines, enhanced government support for cancer research funding, and a rising need for combined cancer treatments. Key trends anticipated over the forecast period encompass the escalating development of therapeutic cancer vaccines, a heightened emphasis on personalized and targeted immunotherapies, more clinical trials for innovative cancer vaccine technologies, the expansion of prophylactic vaccination initiatives to prevent cancer, and increased partnerships between pharmaceutical firms and research institutions.
Get A Free Sample Report With In-Depth Market Insights:
Cancer Vaccines Market Demand Drivers: What’s Powering Industry Growth?
Increased government financial backing for research and development is projected to boost the growth of the cancer vaccines market going forward. Government funding refers to monetary resources provided by a government for a specific aim. This funding for R&D is on the rise to stimulate innovation and expedite the development of new technologies and treatments that can address pressing health and economic challenges. Cancer vaccines support government funding for research and development by creating opportunities for investment in both preventive and therapeutic innovations, encouraging increased financial assistance for vaccine research programs. For instance, in September 2023, the National Cancer Institute, a US-based government agency, received a budget of $7.3 billion from the United States Congress for fiscal year 2023, which signifies a $408 million increase over 2022. Therefore, the rise in government funding for research and development is driving the expansion of the cancer vaccines market.
Cancer Vaccines Market Segment Trends And Revenue Contributors
The cancer vaccines market covered in this report is segmented –
1) By Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
2) By Technology: Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Whole Cell Cancer Vaccines, Viral Vector & DNA Cancer Vaccines
3) By Cancer Type: Prostate, Cervical, Colorectal, Throat, Other Cancer Types
4) By End-User: Cancer Treatment Centers, Research Institutes
Subsegments:
1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines
2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge), Talimogene Laherparepvec (T-VEC), Other Therapeutic Vaccines
Cancer Vaccines Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies operating in the cancer vaccines market are intensifying their efforts to introduce quadrivalent vaccines to maximize revenue in the market. A quadrivalent vaccine is a type of vaccine that offers protection against four different strains or types of a specific virus or bacteria. For instance, in January 2023, Serum Institute of India, an India-based biotechnology company, launched CERVAVAC, which stands as the first made-in-India cervical cancer vaccine. The vaccine is engineered to target HPV types 16 and 18, as well as 6 and 11, strains that are responsible for at least 70% of cervical cancers. The vaccine will be administered by injection in two doses among 9–14-year-olds and three doses for those between 15 and 26.
Cancer Vaccines Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the cancer vaccines market are GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.
View The Full Cancer Vaccines Market Report:
Cancer Vaccines Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the cancer vaccines market in 2025. The regions covered in the cancer vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model